ANPC.F Stock Overview
A medical diagnostic company, engages in developing cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ANGLE plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.16 |
| 52 Week High | UK£0.35 |
| 52 Week Low | UK£0.13 |
| Beta | 0.27 |
| 11 Month Change | 0% |
| 3 Month Change | -18.02% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -90.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| ANPC.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 1.2% | 2.0% |
| 1Y | n/a | 22.6% | 32.4% |
Return vs Industry: Insufficient data to determine how ANPC.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how ANPC.F performed against the US Market.
Price Volatility
| ANPC.F volatility | |
|---|---|
| ANPC.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ANPC.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ANPC.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 150 | Andrew David Newland | angleplc.com |
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated analysis. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with high analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal transition; and CellKeep Slide, a CTC harvesting technology.
ANGLE plc Fundamentals Summary
| ANPC.F fundamental statistics | |
|---|---|
| Market cap | US$60.73m |
| Earnings (TTM) | -US$25.92m |
| Revenue (TTM) | US$2.81m |
21.6x
P/S Ratio-2.3x
P/E RatioIs ANPC.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANPC.F income statement (TTM) | |
|---|---|
| Revenue | UK£2.19m |
| Cost of Revenue | UK£2.59m |
| Gross Profit | -UK£408.00k |
| Other Expenses | UK£19.72m |
| Earnings | -UK£20.13m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.062 |
| Gross Margin | -18.66% |
| Net Profit Margin | -920.95% |
| Debt/Equity Ratio | 0% |
How did ANPC.F perform over the long term?
See historical performance and comparison